EP Wealth Advisors LLC Purchases New Shares in Arrowhead Pharmaceuticals, Inc. $ARWR

EP Wealth Advisors LLC purchased a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 38,135 shares of the biotechnology company's stock, valued at approximately $3,108,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of ARWR. BlackRock Inc. acquired a new stake in shares of Arrowhead Pharmaceuticals during the second quarter valued at approximately $1,208,838,000. Arrowstreet Capital Limited Partnership boosted its stake in Arrowhead Pharmaceuticals by 3,142.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,081,689 shares of the biotechnology company's stock worth $71,797,000 after purchasing an additional 2,017,489 shares during the period. Norges Bank acquired a new position in Arrowhead Pharmaceuticals in the 4th quarter worth approximately $113,159,000. Fred Alger Management LLC grew its position in Arrowhead Pharmaceuticals by 497.4% during the 4th quarter. Fred Alger Management LLC now owns 1,832,997 shares of the biotechnology company's stock worth $121,693,000 after purchasing an additional 1,526,164 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new position in Arrowhead Pharmaceuticals during the 1st quarter worth approximately $64,988,000. Institutional investors and hedge funds own 62.61% of the company's stock.

Insiders Place Their Bets

In other news, Director Michael S. Perry sold 11,600 shares of the company's stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total value of $1,012,680.00. Following the transaction, the director directly owned 111,459 shares of the company's stock, valued at approximately $9,730,370.70. This represents a 9.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Adeoye Y. Olukotun sold 2,000 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total value of $173,920.00. Following the sale, the director owned 31,600 shares of the company's stock, valued at approximately $2,747,936. This represents a 5.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 3.60% of the company's stock.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR opened at $87.11 on Friday. The company has a market capitalization of $12.27 billion, a PE ratio of -38.72 and a beta of 1.27. The company has a debt-to-equity ratio of 1.77, a quick ratio of 5.90 and a current ratio of 5.90. The company's 50 day moving average price is $82.84 and its 200 day moving average price is $72.87. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $20.44 and a 52 week high of $95.49.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.13). The company had revenue of $75.25 million during the quarter, compared to analysts' expectations of $44.17 million. Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%.The firm's quarterly revenue was up 171.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.26) EPS. Research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -3.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on ARWR shares. Piper Sandler reissued an "overweight" rating and set a $126.00 target price (up from $110.00) on shares of Arrowhead Pharmaceuticals in a research note on Thursday, July 23rd. Royal Bank Of Canada raised their target price on Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the stock an "outperform" rating in a research report on Friday, May 8th. B. Riley Financial lifted their price target on Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the company a "buy" rating in a report on Thursday, July 30th. Weiss Ratings reissued a "sell (d-)" rating on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 17th. Finally, Stifel Nicolaus began coverage on Arrowhead Pharmaceuticals in a research report on Tuesday, July 14th. They set a "buy" rating and a $98.00 price target on the stock. Nine equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $97.33.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company's pipeline includes multiple candidates in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source